Not Yet RecruitingNot Applicable

MCG In Long QT Syndrome

United States100 participantsStarted 2026-04

Plain-language summary

The primary objective of this observational study is to evaluate whether magnetocardiography (MCG) findings more accurately predict clinical outcomes in patients with acquired Long QT syndrome compared to ECG. The secondary objective is to assess differences in QT interval length between MCG and ECG. The primary safety objective is to characterize the safety profile of the CardiAQ MCG device.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years on the date of consent
✓. Ability for participant to comply with study requirements
✓. Written informed consent
✓. Confirmed diagnosis of atrial fibrillation and receiving dofetilide for rhythm control in the inpatient setting.

Exclusion criteria

✕. Pregnant or breastfeeding
✕. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillators).
✕. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
✕. Inability to lie down in a supine/inclined position and stay still on the examination bed
✕. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol

What they're measuring

Number of successful dofetilide loading using Magnetocardiography

Timeframe: Baseline

Number of successful dofetilide loading using Electrocardiogram

Timeframe: Baseline

Trial details

NCT IDNCT07270211

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12

Contact for this trial

Patsy Caceres Figueroa

507-266-3054 caceresfigueroa.patsy@mayo.edu

View on ClinicalTrials.gov More Atrial Fibrillation trials